Algeta´s financial calendar 2010

Oslo, Norway, 25 January 2010 - Algeta ASA (OSE:ALGETA), the cancer therapeutics
company, announces it´s financial calendar for 2010

19. Feb. Presentation of the annual accounts (08:00 CET)

22. April General meeting

07. May Presentation of first quarter report (09:45 CET)

13. Aug. Presentation of second quarter report (09:45 CET)

12. Nov. Presentation of third quarter report (09:45 CET)

The presentations will be held at Hotel Continental, Oslo. Algeta reserves the
right to revise the dates. The calendar is available in the report for the third
quarter 2009 and on www.algeta.com.

###

For further information, please contact

Andrew Kay, CEO +47 2300 7990 / +47 4840 1360 (mob)
Øystein Soug, CFO +47 2300 7990 / +47 9065 6525 (mob)
post@algeta.com

International media enquiries: +44 207 638 9571
Mark Swallow/Helena Galilee/David mark.swallow@citigatedr.co.uk
Dible
Citigate Dewe Rogerson

US investor enquiries: +1 646 378 2928
Jessica Lloyd jlloyd@troutgroup.com
The Trout Group

About Algeta
Algeta ASA is a cancer therapeutics company built on world-leading, proprietary
technology. Algeta is developing a new generation of targeted cancer
therapeutics (alpha-pharmaceuticals) that harness the unique characteristics of
alpha particle emitters and are potent, well-tolerated and convenient to use.

Algeta´s lead alpha-pharmaceutical candidate, Alpharadin (based on radium-223),
has blockbuster potential for treating bone metastases arising from multiple
major cancer types, owing to its bone-targeting nature, potent efficacy
(therapeutic and palliative) and benign, placebo-like safety profile.
Development of Alpharadin is most advanced targeting bone metastases resulting
from hormone-refractory prostate cancer (HRPC), and it entered an international
phase III clinical trial (ALSYMPCA) in mid-2008 based on compelling clinical
results from a comprehensive phase II program. This trial is currently open for
recruitment.

In September 2009, Algeta entered into an global agreement with Bayer Healthcare
AG for the development and commercialization of Alpharadin. As part of the
agreement, Algeta retains an option to co-promote Alpharadin in the United
States and to share profits from future sales.

Algeta is also developing other technologies for delivering
alpha-pharmaceuticals. These include methods to enhance the potency of
therapeutic antibodies and other tumor-targeting molecules by linking them to
the alpha particle emitter thorium-227. The Company is headquartered in Oslo,
Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in
March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. There are a number of
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.

###

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)

[HUG#1376950]

Financial calendar 2010: http://hugin.info/134655/R/1376950/338082.pdf